2025
Opioid Dose Variation in Cardiac Surgery: A Multicenter Study of Practice
Fisher C, Janda A, Zhao X, Deng Y, Bardia A, Yanez N, Burns M, Aziz M, Treggiari M, Mathis M, Lin H, Schonberger R. Opioid Dose Variation in Cardiac Surgery: A Multicenter Study of Practice. Anesthesia & Analgesia 2025, 140: 1016-1027. PMID: 39167548, PMCID: PMC11842693, DOI: 10.1213/ane.0000000000007128.Peer-Reviewed Original ResearchCardiac surgeryOpioid doseDose variationIntraoperative opioid administrationIntraoperative opioid doseHigh-dose opioidsAdult cardiac surgerySurgical differencesOpioid-freeOpioid administrationOpioid useMultimodal analgesiaAnalgesic techniquesCardiopulmonary bypassMulticenter studyFentanyl equivalentsSufentanil infusionSurgical patientsOpioidSurgeryAnesthetic techniqueCardiac casesAttending anesthesiologistPatientsDoseMoving beyond desensitization to tolerance in food allergy
Flom J, Shreffler W, Perrett K. Moving beyond desensitization to tolerance in food allergy. The Journal Of Allergy And Clinical Immunology In Practice 2025 PMID: 40010566, DOI: 10.1016/j.jaip.2025.02.014.Peer-Reviewed Original ResearchManagement of IgE-mediated food allergyFood allergyIgE-mediated food allergyStages of clinical developmentSide effect profileMode of deliveryGoal of therapeuticsSustained unresponsivenessDosing regimensDose protocolProactive therapyAllergen-specificClinical developmentActive therapyPatient populationSide effectsTherapyPassive therapyPatient-specificDesensitizationClinical contextPatientsDoseAllergyDegree of protectionAssessing the impact of revising MenACWY vaccination schedule for adolescents in the United States: a modelling study
Shoukat A, Wells C, Shin T, Potter-Schwartz L, Galvani A, Moghadas S. Assessing the impact of revising MenACWY vaccination schedule for adolescents in the United States: a modelling study. The Lancet Regional Health - Americas 2025, 44: 101033. PMID: 40046840, PMCID: PMC11880592, DOI: 10.1016/j.lana.2025.101033.Peer-Reviewed Original ResearchInvasive meningococcal diseaseInvasive meningococcal disease casesVaccination scheduleVaccine uptakeAlternative schedulesMenACWY vaccination programCase fatality rateHigh-risk adolescentsVaccine introductionBooster doseIMD casesSerogroup CCompare outcomesMenACWY vaccineAsymptomatic infectionImmunization PracticesMeningococcal diseaseVaccine effectivenessIMD incidenceDoseSerogroups AVaccineStudy periodVaccination programIncrease vaccine uptakeComputational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories.
Yusufaly T, Roncali E, Brosch-Lenz J, Uribe C, Jha A, Currie G, Dutta J, El-Fakhri G, McMeekin H, Pandit-Taskar N, Schwartz J, Shi K, Strigari L, Zaidi H, Saboury B, Rahmim A. Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories. Journal Of Nuclear Medicine 2025, jnumed.124.267927. PMID: 39947910, DOI: 10.2967/jnumed.124.267927.Peer-Reviewed Original ResearchRadiopharmaceutical therapyImage-based dosimetryPrediction of doseInternal dosimetryPersonalized treatment plansMetastatic diseaseDosimetryNuclear oncologyClinical outcomesNuclear medicineClinical endpointsTreatment planningOncology communityDose responseEtiological mechanismsTargeted deliveryRadiobiologyRadiotherapyMalignancyRadiationLong-termTherapyPharmacotherapyDoseRadiopharmacokineticsSelinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design
Mascarenhas J, Maher K, Rampal R, Bose P, Podoltsev N, Hong J, Chai Y, Kye S, Method M, Harrison C, . Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design. Future Oncology 2025, 21: 807-813. PMID: 39911057, PMCID: PMC11916360, DOI: 10.1080/14796694.2025.2461393.Peer-Reviewed Original ResearchConceptsJAK inhibitorsNo dose limiting toxicitiesDose-limiting toxicityAbsolute mean changeSpleen volume reductionPlacebo-controlled studyBaseline to weekTreatment of patientsDose expansionDose escalationLimiting toxicitiesDouble-blindPrimary endpointPhase 3 study designXPO1 inhibitorsMean changeRuxolitinibPatientsSelinexorVolume reductionDosePhase 3InhibitorsJAKMyelofibrosisEfficacy, safety, and pharmacokinetics of lenacapavir oral bridging when subcutaneous lenacapavir cannot be administered.
Ogbuagu O, Avihingsanon A, Segal-Maurer S, Wang H, Jogiraju V, Singh R, Rhee M, Dvory-Sobol H, Sklar P, Molina J. Efficacy, safety, and pharmacokinetics of lenacapavir oral bridging when subcutaneous lenacapavir cannot be administered. AIDS 2025 PMID: 39912752, DOI: 10.1097/qad.0000000000004142.Peer-Reviewed Original ResearchTreatment-emergent AEClinical trialsVirologic suppressionRates of virologic suppressionPlasma concentrationsAdequate plasma concentrationsHIV-1 treatmentConfidence intervalsLens doseLens treatmentMedian durationLenacapavirSC doseHIV-1PharmacokineticsPosthoc analysisDoseWeeksEfficacyTrialsAnalysis of participantsTreatmentInjectionAntiretroviralsSafetyRegional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
Kopp S, Vandermeulen E, McBane R, Perlas A, Leffert L, Horlocker T. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition). Regional Anesthesia & Pain Medicine 2025, rapm-2024-105766. PMID: 39880411, DOI: 10.1136/rapm-2024-105766.Peer-Reviewed Original ResearchAmerican Society of Regional AnesthesiaDeep venous thrombosisEvidence-based guidelinesRegional anesthesiaThrombolytic therapyComplications associated with regional anesthesiaRecurrent deep venous thrombosisAmerican SocietyRandomized controlled trialsAnticoagulant doseNeural blockadeVenous thrombosisCase seriesCatastrophic complicationPatient characteristicsClinical trialsHigh dosesPatientsPublished guidelinesControlled trialsPainAnesthesiaPatient safetyTherapyDose
2024
Higher Rates of Delay in Starting Advanced Inflammatory Bowel Disease Therapies Linked to Insurance Delays, Intravenous Infusions, and Lack of Pharmacy Support
Gottesman S, Xiao K, Nguyen H, Hernandez E, Saweris E, Jagannathan P, Jafri F, Davis J, Tong K, Tang Z, Gaidos J, Feagins L. Higher Rates of Delay in Starting Advanced Inflammatory Bowel Disease Therapies Linked to Insurance Delays, Intravenous Infusions, and Lack of Pharmacy Support. Clinical And Translational Gastroenterology 2024, 16: e00808. PMID: 39718220, PMCID: PMC11932631, DOI: 10.14309/ctg.0000000000000808.Peer-Reviewed Original ResearchConceptsAdvanced therapiesRisk factorsMulticenter studyMulticenter study of patientsInflammatory bowel disease therapyStudy of patientsAdult inflammatory bowel diseasePatient-related factorsIntravenous drug deliverySmall molecule therapiesLogistic regression analysisInflammatory bowel diseaseBaseline demographicsDisease activityIntravenous infusionMolecule therapiesDisease characteristicsGastroenterology practiceTherapyBowel diseaseInsurance denialPatientsDoseIntravenous inductionCare teamClinical outcomes of a twice-daily metronidazole dosing strategy for Bacteroides spp. bloodstream infections
Shah S, Adams K, Clarke L, Ludwig J, McManus D, Nguyen M, Topal J, Shields R. Clinical outcomes of a twice-daily metronidazole dosing strategy for Bacteroides spp. bloodstream infections. International Journal Of Antimicrobial Agents 2024, 65: 107403. PMID: 39667533, DOI: 10.1016/j.ijantimicag.2024.107403.Peer-Reviewed Original ResearchClinical failureDosing strategiesClinical outcomesIncreased risk of clinical failureRetrospective chart review of adult patientsChart review of adult patientsReview of adult patientsRate of clinical failureClinical outcomes of patientsRisk of clinical failureAssociated with worse outcomesOutcomes of patientsRetrospective chart reviewBloodstream infectionsMetronidazole doseAdult patientsWorse outcomesIncreased riskMetronidazolePatientsInclusion criteriaBacteroides sppBacteremiaDoseMortality156. Safety of Remibrutinib across Immune-mediated Diseases Supports Development in Multiple Sclerosis
Kieseier B, Montalban X, Williams M, Airas L, Saini S, Hide M, Sussman G, Nakahara J, Bermel R, Dörner T, Loop B, DeLasHeras V, Willi R, Haemmerle S, Zharkov A, Barbier N, Azmon A, Siegel R, Cenni B, Haddad I, Wiendl H, Maurer M, Giménez-Arnau A, Chitnis T. 156. Safety of Remibrutinib across Immune-mediated Diseases Supports Development in Multiple Sclerosis. Multiple Sclerosis And Related Disorders 2024, 92: 106117. DOI: 10.1016/j.msard.2024.106117.Peer-Reviewed Original ResearchAdverse eventsSafety profileOral Bruton's tyrosine kinase inhibitorTreatment of relapsing multiple sclerosisBruton tyrosine kinase inhibitorSkin/subcutaneous tissue disordersUpper respiratory tract infectionMultiple sclerosisTyrosine kinase inhibitorsPhase 3 trialRespiratory tract infectionsGrouped adverse eventsIntegrated safety analysisNervous system disordersTreatment discontinuationTract infectionsRemibrutinibTissue disordersKinase inhibitorsSystem disordersOff-target effectsGastrointestinal disordersDoseInfectionPooled dataA Seamless Phase 2A‐Phase 2B Multi‐Center Trial to Test the Benefits of Benfotiamine on the Progression of Alzheimer’s Disease‐Benfoteam: Design and Methods
Luchsinger J, Feldman H, Messer K, Edland S, Leger G, Jacobs D, Salmon D, Revta C, Lupo J, Durant J, Gibson G. A Seamless Phase 2A‐Phase 2B Multi‐Center Trial to Test the Benefits of Benfotiamine on the Progression of Alzheimer’s Disease‐Benfoteam: Design and Methods. Alzheimer's & Dementia 2024, 20: e091963. PMCID: PMC11714007, DOI: 10.1002/alz.091963.Peer-Reviewed Original ResearchPhase 2bDosing decisionsPerson-months of exposureLonger-term safetyWeeks of treatmentCo-primary endpointsClinically significant benefitBiomarker test resultsMulti-center trialTolerated doseDouble-blindEvaluate safetySmall molecule treatmentBlood levelsActive treatmentPhase 2aThiamine deficiencyPerson-monthsDoseCohen's d effect sizesPharmacological effectsTherapeutic directionsBenfotiamineGlucose metabolismMg/dayEffectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023
DeCuir J, Surie D, Zhu Y, Lauring A, Gaglani M, McNeal T, Ghamande S, Peltan I, Brown S, Ginde A, Steinwand A, Mohr N, Gibbs K, Hager D, Ali H, Frosch A, Gong M, Mohamed A, Johnson N, Srinivasan V, Steingrub J, Khan A, Busse L, Duggal A, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughn I, Ramesh M, Safdar B, Mosier J, Casey J, Talbot H, Rice T, Halasa N, Chappell J, Grijalva C, Baughman A, Womack K, Rhoads J, Swan S, Johnson C, Lewis N, Ellington S, Dawood F, McMorrow M, Self W, Network F. Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023. Influenza And Other Respiratory Viruses 2024, 18: e70027. PMID: 39496339, PMCID: PMC11534416, DOI: 10.1111/irv.70027.Peer-Reviewed Original ResearchConceptsCOVID-19-associated hospitalizationIn-hospital outcomesVaccine effectivenessMonovalent dosesAbsolute VETest-negative case-control designInvasive mechanical ventilationCOVID-19 vaccineMultivariate logistic regressionSevere COVID-19Case patientsCase-control designControl patientsMechanical ventilationUnvaccinated patientsPatientsMonovalent vaccineCOVID-19-like illnessDoseCOVID-19 vaccine effectivenessBivalent vaccineLogistic regressionAdmission dateVaccineHospitalCT for Congenital Heart Disease
Fuss C. CT for Congenital Heart Disease. 2024, 277-293. DOI: 10.1007/978-981-97-6919-3_21.Peer-Reviewed Original ResearchCongenital heart diseaseHeart diseaseEvaluation of congenital heart diseaseManagement of congenital heart diseaseContrast doseAffected patientsBirth defectsStages of repairRadiation exposureAltered physiologySmall organ sizeCT roleDiseaseVariable stagesCongenitallyPatientsCTDoseSpatial image resolutionComplexity of defectsBirthBotulinum Toxin Treatment of Psoriasis—A Comprehensive Review
Ghaseminejad-Bandpey A, Etemadmoghadam S, Jabbari B. Botulinum Toxin Treatment of Psoriasis—A Comprehensive Review. Toxins 2024, 16: 449. PMID: 39453225, PMCID: PMC11510791, DOI: 10.3390/toxins16100449.Peer-Reviewed Original ResearchConceptsOpen-label studyClinical trialsAnimal studiesPlacebo-controlled studyInjection of botulinum toxinPsoriatic skin lesionsLevels of interleukinsBotulinum toxin injectionOpen-labelDouble-blindBotulinum toxin treatmentCase reportInflammatory cellsPsoriatic plaquesSkin lesionsSmall dosesToxin injectionToxin treatmentLiterature searchBotulinum toxinRelevant articlesPsoriasisInterleukinHuman dataDoseModelling vaccination approaches for mpox containment and mitigation in the Democratic Republic of the Congo
Savinkina A, Kindrachuk J, Bogoch I, Rimoin A, Hoff N, Shaw S, Pitzer V, Mbala-Kingebeni P, Gonsalves G. Modelling vaccination approaches for mpox containment and mitigation in the Democratic Republic of the Congo. The Lancet Global Health 2024, 12: e1936-e1944. PMID: 39393385, DOI: 10.1016/s2214-109x(24)00384-x.Peer-Reviewed Original ResearchTwo-dose priming immunization amplifies humoral immunity by synchronizing vaccine delivery with the germinal center response
Bhagchandani S, Yang L, Lam J, Maiorino L, Ben-Akiva E, Rodrigues K, Romanov A, Suh H, Aung A, Wu S, Wadhera A, Chakraborty A, Irvine D. Two-dose priming immunization amplifies humoral immunity by synchronizing vaccine delivery with the germinal center response. Science Immunology 2024, 9: eadl3755-eadl3755. PMID: 39303017, PMCID: PMC11492009, DOI: 10.1126/sciimmunol.adl3755.Peer-Reviewed Original ResearchConceptsDendritic cellsGerminal centersHumoral immunityAntigen-specific germinal centerGerminal center responseSubunit vaccineFollicular dendritic cellsPrimary immune responseIncreased T<sub>rDose 7 daysPrime immunizationGC responseImmune responseVaccine deliveryCenter responseAdministered vaccinesImmunityVaccineRegimensAdjuvant vaccineDoseCellsHIVResponseBolusMechanistic Differences between Torsemide and Furosemide
Rao V, Cox Z, Ivey-Miranda J, Neville D, Balkcom N, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Tang W, Collins S, Velazquez E, Mentz R, Wilson F, Turner J, Wilcox C, Ellison D, Fang J, Testani J. Mechanistic Differences between Torsemide and Furosemide. Journal Of The American Society Of Nephrology 2024, 36: 99-107. PMID: 39196651, PMCID: PMC11706557, DOI: 10.1681/asn.0000000000000481.Peer-Reviewed Original ResearchTorsemide groupDiuretic doseTubular site of actionHigher diuretic dosesDose of furosemideProportion of dosesOral furosemideSite of actionPrescribed doseNeurohormonal activationMechanistic substudyClinical outcomesPharmacodynamic advantagesKidney dysfunctionPharmacodynamic parametersKidney functionRandomized trialsNatriuresisTubular sitesFurosemideTorsemideDoseTRANSFORM-HFPlasma volumeBody weightLicensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus
Khurana S, King L, Manischewitz J, Posadas O, Mishra A, Liu D, Beigel J, Rappuoli R, Tsang J, Golding H. Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus. Nature Medicine 2024, 30: 2771-2776. PMID: 39013430, DOI: 10.1038/s41591-024-03189-y.Peer-Reviewed Original ResearchCross-neutralizing antibodiesH5N1 vaccineNeutralizing antibody responsesVaccination of adultsDevelopment of effective vaccinesGlobal public health threatHPAI H5N1Influenza virusSeroconversion ratesH5N1Neutralizing antibodiesCross-reactive bindingPublic health threatLicensed vaccinesHemagglutination inhibitionPublic health priorityAntibody responseEffective vaccineHPAIVaccineAntibodiesDoseHealth priorityVirusHealth threatSacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer
Greenman M, Bellone S, Demirkiran C, Hartwich T, Santin A. Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer. Gynecologic Oncology Reports 2024, 54: 101459. PMID: 39108617, PMCID: PMC11300917, DOI: 10.1016/j.gore.2024.101459.Peer-Reviewed Original ResearchHigh grade serous ovarian cancerAntibody-drug conjugatesSerous ovarian cancerSacituzumab govitecanOvarian cancerTreatment optionsPlatinum-resistant ovarian cancer patientsDose-limiting toxicityOvarian cancer patientsNovel treatment optionsPartial responseRecurrent diseaseDose reductionCancer patientsClinical trialsBackground treatmentTargeted treatmentChemotherapyTreatmentCancerDoseDiseaseOptionsTrop2PatientsPulsed nicotine infusions as a model for smoking: validating a tool to explore nicotine thresholds in humans
Parida S, MacLean R, Gueorguieva R, Sofuoglu M. Pulsed nicotine infusions as a model for smoking: validating a tool to explore nicotine thresholds in humans. Psychopharmacology 2024, 241: 1915-1922. PMID: 38970644, DOI: 10.1007/s00213-024-06609-6.Peer-Reviewed Original ResearchDiscriminative stimulus effectsAddiction thresholdNicotine doseDiscriminative stimulus effects of nicotineStimulus effects of nicotineNicotine deliveryEffects of nicotineOvernight abstinenceStimulus effectsNicotine infusionSubjective effectsTest sessionsNicotineMethodsEleven participantsInfusion procedureLow dosesParticipantsThreshold doseConclusionsTheseAbstinenceDoseHeart rateInfusionSmokingObjectivesTo
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply